Amgen and Watson Pharmaceuticals have formed a global collaboration to develop and commercialise biosimilar versions of oncology antibody therapeutics. Watson will fund up to US$400 M in co-development costs, while Amgen will assume primary responsibility for the development, manufacture and initial commercialisation of the biosimilars. Although the parties did not specify which biosimilars would be developed, the collaboration will not pursue biosimilar versions of Amgen’s proprietary products. The deal is the latest in a series of collaborations focused on the development of follow-on biologics.